Day on Torts

NOVEMBER 15, 2022

When a litigant has filed a motion to dismiss pursuant to the Tennessee Public Participation Act (TPPA), that motion should be analyzed under the provisions of the TPPA rather than under the traditional Tennessee Rule of Civil Procedure 12 analysis. Rock Creek Construction, Inc. , The Court of Appeals quoted Tenn. In Reiss v.

Prima Facie Case 59

Prima Facie Case Tort Statute Construction 59

Patently O

NOVEMBER 29, 2023

by Dennis Crouch The Supreme Court is set to consider several significant patent law petitions addressing a range of issues from the application of obviousness standards, challenges to PTAB procedures, interpretation of joinder time limits IPR, to the proper scope patent eligibility doctrine. More detail on each case below: MacNeil v.

Court 75

Court Prima Facie Case Laws Technology 75

Patently O

APRIL 1, 2024

by Dennis Crouch In April 2024, the Federal Circuit issued a significant decision vacating a district court’s judgment that Janssen Pharmaceuticals’ dosing regimen patent claims were nonobvious. The case involved Janson’s U.S. Overall, this is a bad case for pharmaceutical formulary patents. Janssen Pharms.,

Prima Facie Case 40

Prima Facie Case Court Litigation Litigating 40